drugset / Trial / NCT00515788
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
Phase 1
Terminated
11 enrolled
M.D. Anderson Cancer Center
Enzon Pharmaceuticals, Inc. · collabSchering-Plough · collab
NaSingle-groupOpen-labelTreatment
Summary
Objectives: \- To determine the safety, tolerability and maximum tolerated dose (MTD) of oral temozolomide using a 7 days on and 7 days off regimen combined with intrathecal liposomal cytarabine (DepoCyt) in patients with neoplastic meningitis from solid tumors and systemic lymphoma.
Timeline
- Start
- 2006-02
- Primary completion
- 2009-06
- Completion
- 2009-06
Outcome
Outcome not reported
Stopped (Enrollment): “Study terminated due to slow accrual with no expansion to additional phase.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 50 mg | Intrathecal |
| Subject | Temozolomide | Small molecule | 100 mg/m2 | Oral |